Literature DB >> 28460841

Low Endogenous Fibroblast Growth Factor 2 Levels Are Associated With Heightened Conditioned Fear Expression in Rats and Humans.

Bronwyn M Graham1, Dino Zagic2, Rick Richardson2.   

Abstract

BACKGROUND: Hippocampal concentrations of the neurotrophic factor fibroblast growth factor 2 (FGF2) are negatively associated with the expression of fear following conditioning in rats. Heightened conditioned fear expression may be a prospective risk factor for the development of human anxiety and trauma disorders. However, the relationship between conditioned fear expression and FGF2 is yet to be established in humans.
METHODS: Using a cross-species approach, we first investigated the relationship between serum concentrations of FGF2 and individual differences in conditioned fear expression in rats (n = 19). We then subjected 88 human participants, who were recruited from university and community advertisements, to a differential fear conditioning procedure and assessed the relationship between salivary concentrations of FGF2 and fear expression to a conditioned stimulus (CS) (a stimulus paired with a shock) and a CS that was never paired with shock.
RESULTS: Rats with low serum levels of FGF2 exhibited significantly more freezing than rats with high serum levels of FGF2. Similarly, relative to those with high salivary FGF2, human participants with low salivary FGF2 exhibited significantly heightened skin conductance responses to the CS without shock during fear conditioning and to both the CS with shock and CS without shock during fear recall.
CONCLUSIONS: These studies establish that peripheral markers of FGF2 concentrations are negatively associated with fear expression in both rats and humans. To the extent that conditioned fear expression predicts anxiety and trauma disorder vulnerability, FGF2 may be a clinically useful biomarker in the prediction and eventual prevention of these disorders.
Copyright © 2017 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Fear conditioning; Fibroblast growth factor 2; Generalization; Individual differences; Safety learning

Mesh:

Substances:

Year:  2017        PMID: 28460841     DOI: 10.1016/j.biopsych.2017.03.020

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

1.  Individual Differences Make a Marker in Fear Research.

Authors:  Katherine E Prater
Journal:  Biol Psychiatry       Date:  2017-10-15       Impact factor: 13.382

2.  Chronic fluoxetine enhances extinction therapy for PTSD by evaluating brain glucose metabolism in rats: an [18F]FDG PET study.

Authors:  Jing Liu; Jun Yu; Hong Biao Liu; Qiong Yao; Ying Zhang
Journal:  Ann Nucl Med       Date:  2022-09-30       Impact factor: 2.258

3.  The Association Between Salivary FGF2 and Physiological and Psychological Components of the Human Stress Response.

Authors:  Emma M Bryant; Rick Richardson; Bronwyn M Graham
Journal:  Chronic Stress (Thousand Oaks)       Date:  2022-07-18

Review 4.  The Molecular Basis of Resilience: A Narrative Review.

Authors:  Megan Ryan; Rebecca Ryznar
Journal:  Front Psychiatry       Date:  2022-05-06       Impact factor: 5.435

5.  Individual differences in conditioned fear are associated with levels of adolescent/early adult alcohol consumption and instrumental extinction.

Authors:  Alisa Pajser; Morgan Breen; Hayley Fisher; Charles L Pickens
Journal:  Behav Brain Res       Date:  2018-04-22       Impact factor: 3.332

6.  Fibroblast Growth Factor 2 Implicated in Childhood Anxiety and Depression Symptoms.

Authors:  Eli R Lebowitz; Meital Orbach; Carla E Marin; Natalina Salmaso; Flora M Vaccarino; Wendy K Silverman
Journal:  J Affect Disord       Date:  2021-01-11       Impact factor: 4.839

7.  Fibroblast Growth Factor-2: A Promising Biomarker for Anxiety and Trauma Disorders.

Authors:  Bronwyn M Graham
Journal:  J Exp Neurosci       Date:  2017-12-19

8.  Analytical Value of Cell-Free DNA Based on Alu in Psychiatric Disorders.

Authors:  Jing Qi; Ling-Yun Chen; Xian-Juan Shen; Shao-Qing Ju
Journal:  Front Psychiatry       Date:  2020-01-21       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.